Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single‐ and Multiple‐Dose Study
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70115 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jart A F Oosterhaven und 13 weiteren Autor:innen. Beteiligte Einrichtung: ICON Plc, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus 3C Proteases, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low‐molecular‐weight inhibitor of the coronavirus main protease (M pro ). This first‐in‐human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo‐controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open‐label, three‐period, six sequence, randomized, cross‐over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose‐dependent or dose‐limiting adverse effects. EGT710 was rapidly absorbed (median T max 2.0 h), showed sub‐proportional AUC and C max increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased C max by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICON Plc, Groningen, The Netherlands.
- CA CSI CVM, Biomedical Research, Novartis, Cambridge, MA, USA.
- Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG, Basel, Switzerland.
- Early Development Analytics, Development, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA.
- Preclinical Safety, Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
- Preclinical Safety, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Zitieren
APA
Oosterhaven, J. A. F., Trolander, J., Bebrevska, L., Schiller, H., Alaybeyoglu, B., Gaudet, S., Claas, A., Balavenkatraman, K. K., Bergeron, R., Duraes, F. V., Chaperon, F., Ghanshani, S., Goncalves, E., & Kovacs, S. J. (2026). Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single‐ and Multiple‐Dose Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70115
Vancouver
Oosterhaven JAF, Trolander J, Bebrevska L, Schiller H, Alaybeyoglu B, Gaudet S, et al. Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single‐ and Multiple‐Dose Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70115
BibTeX
@article{Oosterhaven2026,
author = {Oosterhaven, Jart A F and Trolander, Jonathan and Bebrevska, Lidiya and Schiller, Hilmar and Alaybeyoglu, Begum and Gaudet, Suzanne and Claas, Allison and Balavenkatraman, Kamal Kumar and Bergeron, Renee and Duraes, Fernanda V and Chaperon, Frederique and Ghanshani, Swati and Goncalves, Elisabete and Kovacs, Steven J},
title = {Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single‐ and Multiple‐Dose Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70115}
}
EUVIMED